Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are two GLP-1-class active pharmaceutical ingredients used in FDA-approved injectable medications for weight management. Brand-name semaglutide products include Ozempic® (type 2 diabetes) and Wegovy® (chronic weight management), both manufactured by Novo Nordisk. Brand-name tirzepatide products include Mounjaro® (type 2 diabetes) and Zepbound® (chronic weight management), both manufactured by Eli Lilly. Semaglutide is a single-receptor GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. Weight Method does not dispense or prescribe brand-name Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide or compounded tirzepatide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded medications are not FDA-approved.

Semaglutide is a single-receptor GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. Brand-name Wegovy® and Zepbound® are both FDA-approved for chronic weight management; Wegovy® was approved in June 2021 and Zepbound® in November 2023. Both are once-weekly injections that require dose escalation. Weight Method's compounded semaglutide program starts at $154/month and compounded tirzepatide at $329/month, all-inclusive. Compounded medications are not FDA-approved and have not been reviewed by FDA for safety, efficacy, or manufacturing quality.